GSE71730

Plasma induced signatures reveal an extracellular milieu possessing an immunoregulatory bias in treatment naïve inflammatory bowel disease

Whole-study status Not suitable

Dataset does not meet the current suitability threshold.

Whole-study downloads — these do not apply your sample requirements.

Selected cohort requirements

Samples meeting selected requirements: 0 cases / 0 controls

View matching samples

Patient pairs verified in indexed sample metadata: 0

A case/control comparison meeting these requirements is not confirmed.

Counts describe samples, not independent patients. Pair verification uses explicit subject identifiers in indexed sample metadata. Zero verified pairs does not establish that the study is unpaired; reported matched-normal design alone is insufficient.

Summary

The complex milieu of inflammatory mediators associated with many diseases is often too dilute to directly measure in the periphery, necessitating development of more sensitive measurements suitable for mechanistic studies, earlier diagnosis, guiding selection of therapy, and monitoring interventions. Previously, we determined that plasma of recent-onset (RO) Type 1 diabetes (T1D) patients induce a proinflammatory transcriptional signature in fresh peripheral blood mononuclear cells (PBMC) relative to that of unrelated healthy controls (HC). Here, using an optimized cryopreserved PBMC-based protocol, we apply this approach to inflammatory bowel disease by examining groups of Crohn's disease (CD) and ulcerative colitus (UC) patients. The induced plasma induced signatures are compared to those of Type 1 diabetes patients (RO T1D) as well as unrelated healthy controls (uHC).

Overall design

UPN727 cells were stimulated with CD plasma (n=22), UC plasma (n=15), Unrelated healthy control (n=10). Gene expression analysis was perfromed in order to evaluate the transcriptional signature associated with IBD.

Source Evidence

4 sources
Source Contribution Status
GEO

Original dataset metadata, sample metadata, source links, and GEO data availability flags.

Sample records
47 GSM samples
Primary source
recount3

Planned trusted source for processed count availability.

No match found
Expression Atlas

Planned source for curated expression experiment links.

No match found
PubMed

Primary GEO citations and related PubMed articles that mention this dataset.

3 linked publications 3 DOIs

Primary publication

  1. Plasma-induced signatures reveal an extracellular milieu possessing an immunoregulatory bias in treatment-naive paediatric inflammatory bowel disease. Clinical and experimental immunology, 2016

Related publications

  1. Blood transcriptomics identifies FEZ1 as a potential biomarker for inflammatory bowel disease. Computers in biology and medicine, 2025
  2. Aimed at Subtype Discrimination but Yielding a Shared Marker: Integrative Analysis of Blood Transcriptomes Reveals Upregulated TLR5 as a Potential Biomarker for IBD. Clinical and experimental gastroenterology, 2026
Available

Metadata Quality Components

Analysis Readiness

Review before analysis
85% DE readiness

Contrast completeness

25/25 pts

Both case and control groups are present in the proposed grouping.

Minimum group size

20/20 pts

Each contrast group has at least 2 samples.

Processed data availability

20/20 pts

Processed data is marked available in the GEO index.

Sample decision clarity

3/15 pts

Unassigned or review-needed samples remain before analysis.

Blocking warnings

7/10 pts

Warnings are present, but none are critical blockers.

Metadata normalization

10/10 pts

Metadata quality is high enough to support downstream handoff.

Blockers

  • 47 samples need manual grouping review.

Next Steps

  • Resolve unassigned or review-needed samples in the grouping table.

Analysis Preparation Checklist

4/6 ready

Group labels reviewed

Needs review

Siftome proposed case and control labels, but no reviewer confirmation is stored yet.

Open the sample grouping CSV and confirm group labels before analysis.

Minimum sample count met

Ready

Both groups meet the minimum of 2 samples.

Confirm whether the cohort is large enough for the intended statistical analysis.

Processed counts available

Ready

Processed data availability is marked true in the GEO index.

Verify that downloaded processed files contain usable count or expression identifiers.

Ambiguous samples handled

Needs review

47 review-needed samples and 0 unassigned samples remain.

Resolve ambiguous and unassigned samples before finalizing the contrast.

Exclusion decisions recorded

Ready

No hard-excluded samples were detected by the current rules.

Record any manual exclusions in the downstream analysis notes.

Source traceability preserved

Ready

The dataset and sample accessions can be traced back to GEO.

Keep GEO accessions with exported metadata.

Bioinformatician Review

Bioinformatician review required

Ask a bioinformatician to review grouping, count availability, exclusions, and design before DE.

Analysis readiness has blockers that must be resolved before DE.

One or more samples were flagged for manual review.

Assay context may require expert handling before DESeq2-style analysis.

Why This Is Ranked Here

Tumor vs normal
Not suitable Dataset does not meet the current suitability threshold.

Applied Review Decisions

No active review decisions affect this ranking.

Derived Classifications

  • Assay differs from search intent Microarray Search intent expects bulk RNA-seq. Assay came from Normalization rules.
  • Disease context Crohn's disease, inflammatory bowel disease, type 1 diabetes, ulcerative colitis Disease context came from Normalization rules.
  • Likely case group Crohn's disease 37 samples
  • Likely control group Healthy control 10 samples

Intent Interpretation

  • Downgrade or exclusion reason Downgraded for tissue search because it is a model-system experiment. Derived from current-intent ranking reasons.

Ranking Facts

Supporting evidence

  • Comparison: Treatment vs control. Specimen: Cell line. Comparison suitability: 0%.
  • Interpreted disease metadata: Crohn's disease, Inflammatory bowel disease, Metabolic disease, Type 1 diabetes, Ulcerative colitis.
  • Processed data is available for downstream review.
  • External evidence: PubMed links 3 publications; 3 DOIs available: PMID 26660358, PMID 39894009, PMID 42112146.
  • Publication context: Plasma-induced signatures reveal an extracellular milieu possessing an immunoregulatory bias in treatment-naive paediatric inflammatory bowel disease.. Clinical and experimental immunology, 2016. PMID 26660358. DOI 10.1111/cei.12753.
  • Publication context: Blood transcriptomics identifies FEZ1 as a potential biomarker for inflammatory bowel disease.. Computers in biology and medicine, 2025. PMID 39894009. DOI 10.1016/j.compbiomed.2025.109742.
  • Publication context: Aimed at Subtype Discrimination but Yielding a Shared Marker: Integrative Analysis of Blood Transcriptomes Reveals Upregulated TLR5 as a Potential Biomarker for IBD.. Clinical and experimental gastroenterology, 2026. PMID 42112146. DOI 10.2147/CEG.S584999.

Cautions

  • Downgraded for tissue search because it is a model-system experiment.
  • Downgraded for tissue search because it is a treatment/control experiment.
  • Downgraded assay: microarray cohorts are separated from the RNA-seq intent.
  • Excluded sample type flags reduce suitability.
  • Treatment/control experiment downgraded because this ranking targets tumor-vs-normal tissue comparisons.
  • Organoid or cell-line experiment downgraded for patient tissue search intent.
  • Excluded model-system sample markers reduce suitability.
  • Overall score capped because comparison suitability is weak for the selected search intent.
  • Comparison suitability score is below the Phase 1 recommended threshold.

Dataset Warnings

Normalized Fields

214 fields

Sample Group Preview

47 rows shown
Show Hide
Study totals: Case 37 | Control 10 | Unassigned 0 | Excluded 0 | Ambiguous 0 47 rows shown
Group Role Accession Title Source / characteristics Reason
Crohn's disease Case GSM1844262 UPN727 cells, Crohn’s disease (CD) plasma patients 01 UPN727 cells stimulated with CD01 Plasma Responder cell line: UPN727; Diagnosis of plasma donor: Crohn’s disease (CD) cell line: Standalone model-system marker retained for comparison grouping: cell line.; treated sample: Treated sample may need exclusion outside treatment comparisons.
Crohn's disease Case GSM1844263 UPN727 cells, Crohn’s disease (CD) plasma patients 02 UPN727 cells stimulated with CD02 Plasma Responder cell line: UPN727; Diagnosis of plasma donor: Crohn’s disease (CD) cell line: Standalone model-system marker retained for comparison grouping: cell line.; treated sample: Treated sample may need exclusion outside treatment comparisons.
Crohn's disease Case GSM1844264 UPN727 cells, Crohn’s disease (CD) plasma patients 03 UPN727 cells stimulated with CD03 Plasma Responder cell line: UPN727; Diagnosis of plasma donor: Crohn’s disease (CD) cell line: Standalone model-system marker retained for comparison grouping: cell line.; treated sample: Treated sample may need exclusion outside treatment comparisons.
Crohn's disease Case GSM1844265 UPN727 cells, Crohn’s disease (CD) plasma patients 04 UPN727 cells stimulated with CD04 Plasma Responder cell line: UPN727; Diagnosis of plasma donor: Crohn’s disease (CD) cell line: Standalone model-system marker retained for comparison grouping: cell line.; treated sample: Treated sample may need exclusion outside treatment comparisons.
Crohn's disease Case GSM1844266 UPN727 cells, Crohn’s disease (CD) plasma patients 05 UPN727 cells stimulated with CD05 Plasma Responder cell line: UPN727; Diagnosis of plasma donor: Crohn’s disease (CD) cell line: Standalone model-system marker retained for comparison grouping: cell line.; treated sample: Treated sample may need exclusion outside treatment comparisons.
Crohn's disease Case GSM1844267 UPN727 cells, Crohn’s disease (CD) plasma patients 06 UPN727 cells stimulated with CD06 Plasma Responder cell line: UPN727; Diagnosis of plasma donor: Crohn’s disease (CD) cell line: Standalone model-system marker retained for comparison grouping: cell line.; treated sample: Treated sample may need exclusion outside treatment comparisons.
Crohn's disease Case GSM1844268 UPN727 cells, Crohn’s disease (CD) plasma patients 07 UPN727 cells stimulated with CD07 Plasma Responder cell line: UPN727; Diagnosis of plasma donor: Crohn’s disease (CD) cell line: Standalone model-system marker retained for comparison grouping: cell line.; treated sample: Treated sample may need exclusion outside treatment comparisons.
Crohn's disease Case GSM1844269 UPN727 cells, Crohn’s disease (CD) plasma patients 08 UPN727 cells stimulated with CD08 Plasma Responder cell line: UPN727; Diagnosis of plasma donor: Crohn’s disease (CD) cell line: Standalone model-system marker retained for comparison grouping: cell line.; treated sample: Treated sample may need exclusion outside treatment comparisons.
Crohn's disease Case GSM1844270 UPN727 cells, Crohn’s disease (CD) plasma patients 09 UPN727 cells stimulated with CD09 Plasma Responder cell line: UPN727; Diagnosis of plasma donor: Crohn’s disease (CD) cell line: Standalone model-system marker retained for comparison grouping: cell line.; treated sample: Treated sample may need exclusion outside treatment comparisons.
Crohn's disease Case GSM1844271 UPN727 cells, Crohn’s disease (CD) plasma patients 10 UPN727 cells stimulated with CD10 Plasma Responder cell line: UPN727; Diagnosis of plasma donor: Crohn’s disease (CD) cell line: Standalone model-system marker retained for comparison grouping: cell line.; treated sample: Treated sample may need exclusion outside treatment comparisons.
Crohn's disease Case GSM1844272 UPN727 cells, Crohn’s disease (CD) plasma patients 11 UPN727 cells stimulated with CD11 Plasma Responder cell line: UPN727; Diagnosis of plasma donor: Crohn’s disease (CD) cell line: Standalone model-system marker retained for comparison grouping: cell line.; treated sample: Treated sample may need exclusion outside treatment comparisons.
Crohn's disease Case GSM1844273 UPN727 cells, Crohn’s disease (CD) plasma patients 12 UPN727 cells stimulated with CD12 Plasma Responder cell line: UPN727; Diagnosis of plasma donor: Crohn’s disease (CD) cell line: Standalone model-system marker retained for comparison grouping: cell line.; treated sample: Treated sample may need exclusion outside treatment comparisons.
Crohn's disease Case GSM1844274 UPN727 cells, Crohn’s disease (CD) plasma patients 13 UPN727 cells stimulated with CD13 Plasma Responder cell line: UPN727; Diagnosis of plasma donor: Crohn’s disease (CD) cell line: Standalone model-system marker retained for comparison grouping: cell line.; treated sample: Treated sample may need exclusion outside treatment comparisons.
Crohn's disease Case GSM1844275 UPN727 cells, Crohn’s disease (CD) plasma patients 14 UPN727 cells stimulated with CD14 Plasma Responder cell line: UPN727; Diagnosis of plasma donor: Crohn’s disease (CD) cell line: Standalone model-system marker retained for comparison grouping: cell line.; treated sample: Treated sample may need exclusion outside treatment comparisons.
Crohn's disease Case GSM1844276 UPN727 cells, Crohn’s disease (CD) plasma patients 15 UPN727 cells stimulated with CD15 Plasma Responder cell line: UPN727; Diagnosis of plasma donor: Crohn’s disease (CD) cell line: Standalone model-system marker retained for comparison grouping: cell line.; treated sample: Treated sample may need exclusion outside treatment comparisons.
Crohn's disease Case GSM1844277 UPN727 cells, Crohn’s disease (CD) plasma patients 16 UPN727 cells stimulated with CD16 Plasma Responder cell line: UPN727; Diagnosis of plasma donor: Crohn’s disease (CD) cell line: Standalone model-system marker retained for comparison grouping: cell line.; treated sample: Treated sample may need exclusion outside treatment comparisons.
Crohn's disease Case GSM1844278 UPN727 cells, Crohn’s disease (CD) plasma patients 17 UPN727 cells stimulated with CD17 Plasma Responder cell line: UPN727; Diagnosis of plasma donor: Crohn’s disease (CD) cell line: Standalone model-system marker retained for comparison grouping: cell line.; treated sample: Treated sample may need exclusion outside treatment comparisons.
Crohn's disease Case GSM1844279 UPN727 cells, Crohn’s disease (CD) plasma patients 18 UPN727 cells stimulated with CD18 Plasma Responder cell line: UPN727; Diagnosis of plasma donor: Crohn’s disease (CD) cell line: Standalone model-system marker retained for comparison grouping: cell line.; treated sample: Treated sample may need exclusion outside treatment comparisons.
Crohn's disease Case GSM1844280 UPN727 cells, Crohn’s disease (CD) plasma patients 19 UPN727 cells stimulated with CD19 Plasma Responder cell line: UPN727; Diagnosis of plasma donor: Crohn’s disease (CD) cell line: Standalone model-system marker retained for comparison grouping: cell line.; treated sample: Treated sample may need exclusion outside treatment comparisons.
Crohn's disease Case GSM1844281 UPN727 cells, Crohn’s disease (CD) plasma patients 20 UPN727 cells stimulated with CD20 Plasma Responder cell line: UPN727; Diagnosis of plasma donor: Crohn’s disease (CD) cell line: Standalone model-system marker retained for comparison grouping: cell line.; treated sample: Treated sample may need exclusion outside treatment comparisons.
Crohn's disease Case GSM1844282 UPN727 cells, Crohn’s disease (CD) plasma patients 21 UPN727 cells stimulated with CD21 Plasma Responder cell line: UPN727; Diagnosis of plasma donor: Crohn’s disease (CD) cell line: Standalone model-system marker retained for comparison grouping: cell line.; treated sample: Treated sample may need exclusion outside treatment comparisons.
Crohn's disease Case GSM1844283 UPN727 cells, Crohn’s disease (CD) plasma patients 22 UPN727 cells stimulated with CD22 Plasma Responder cell line: UPN727; Diagnosis of plasma donor: Crohn’s disease (CD) cell line: Standalone model-system marker retained for comparison grouping: cell line.; treated sample: Treated sample may need exclusion outside treatment comparisons.
Ulcerative colitis Case GSM1844284 UPN727 cells, ulcerative colitis (UC) plasma patients 01 UPN727 cells stimulated with UC01 Plasma Responder cell line: UPN727; Diagnosis of plasma donor: Ulcerative colitis (UC) cell line: Standalone model-system marker retained for comparison grouping: cell line.; treated sample: Treated sample may need exclusion outside treatment comparisons.
Ulcerative colitis Case GSM1844285 UPN727 cells, ulcerative colitis (UC) plasma patients 02 UPN727 cells stimulated with UC02 Plasma Responder cell line: UPN727; Diagnosis of plasma donor: Ulcerative colitis (UC) cell line: Standalone model-system marker retained for comparison grouping: cell line.; treated sample: Treated sample may need exclusion outside treatment comparisons.
Ulcerative colitis Case GSM1844286 UPN727 cells, ulcerative colitis (UC) plasma patients 03 UPN727 cells stimulated with UC03 Plasma Responder cell line: UPN727; Diagnosis of plasma donor: Ulcerative colitis (UC) cell line: Standalone model-system marker retained for comparison grouping: cell line.; treated sample: Treated sample may need exclusion outside treatment comparisons.
Ulcerative colitis Case GSM1844287 UPN727 cells, ulcerative colitis (UC) plasma patients 04 UPN727 cells stimulated with UC04 Plasma Responder cell line: UPN727; Diagnosis of plasma donor: Ulcerative colitis (UC) cell line: Standalone model-system marker retained for comparison grouping: cell line.; treated sample: Treated sample may need exclusion outside treatment comparisons.
Ulcerative colitis Case GSM1844288 UPN727 cells, ulcerative colitis (UC) plasma patients 05 UPN727 cells stimulated with UC05 Plasma Responder cell line: UPN727; Diagnosis of plasma donor: Ulcerative colitis (UC) cell line: Standalone model-system marker retained for comparison grouping: cell line.; treated sample: Treated sample may need exclusion outside treatment comparisons.
Ulcerative colitis Case GSM1844289 UPN727 cells, ulcerative colitis (UC) plasma patients 06 UPN727 cells stimulated with UC06 Plasma Responder cell line: UPN727; Diagnosis of plasma donor: Ulcerative colitis (UC) cell line: Standalone model-system marker retained for comparison grouping: cell line.; treated sample: Treated sample may need exclusion outside treatment comparisons.
Ulcerative colitis Case GSM1844290 UPN727 cells, ulcerative colitis (UC) plasma patients 07 UPN727 cells stimulated with UC07 Plasma Responder cell line: UPN727; Diagnosis of plasma donor: Ulcerative colitis (UC) cell line: Standalone model-system marker retained for comparison grouping: cell line.; treated sample: Treated sample may need exclusion outside treatment comparisons.
Ulcerative colitis Case GSM1844291 UPN727 cells, ulcerative colitis (UC) plasma patients 08 UPN727 cells stimulated with UC08 Plasma Responder cell line: UPN727; Diagnosis of plasma donor: Ulcerative colitis (UC) cell line: Standalone model-system marker retained for comparison grouping: cell line.; treated sample: Treated sample may need exclusion outside treatment comparisons.
Ulcerative colitis Case GSM1844292 UPN727 cells, ulcerative colitis (UC) plasma patients 09 UPN727 cells stimulated with UC09 Plasma Responder cell line: UPN727; Diagnosis of plasma donor: Ulcerative colitis (UC) cell line: Standalone model-system marker retained for comparison grouping: cell line.; treated sample: Treated sample may need exclusion outside treatment comparisons.
Ulcerative colitis Case GSM1844293 UPN727 cells, ulcerative colitis (UC) plasma patients 10 UPN727 cells stimulated with UC10 Plasma Responder cell line: UPN727; Diagnosis of plasma donor: Ulcerative colitis (UC) cell line: Standalone model-system marker retained for comparison grouping: cell line.; treated sample: Treated sample may need exclusion outside treatment comparisons.
Ulcerative colitis Case GSM1844294 UPN727 cells, ulcerative colitis (UC) plasma patients 11 UPN727 cells stimulated with UC11 Plasma Responder cell line: UPN727; Diagnosis of plasma donor: Ulcerative colitis (UC) cell line: Standalone model-system marker retained for comparison grouping: cell line.; treated sample: Treated sample may need exclusion outside treatment comparisons.
Ulcerative colitis Case GSM1844295 UPN727 cells, ulcerative colitis (UC) plasma patients 12 UPN727 cells stimulated with UC12 Plasma Responder cell line: UPN727; Diagnosis of plasma donor: Ulcerative colitis (UC) cell line: Standalone model-system marker retained for comparison grouping: cell line.; treated sample: Treated sample may need exclusion outside treatment comparisons.
Ulcerative colitis Case GSM1844296 UPN727 cells, ulcerative colitis (UC) plasma patients 13 UPN727 cells stimulated with UC13 Plasma Responder cell line: UPN727; Diagnosis of plasma donor: Ulcerative colitis (UC) cell line: Standalone model-system marker retained for comparison grouping: cell line.; treated sample: Treated sample may need exclusion outside treatment comparisons.
Ulcerative colitis Case GSM1844297 UPN727 cells, ulcerative colitis (UC) plasma patients 14 UPN727 cells stimulated with UC14 Plasma Responder cell line: UPN727; Diagnosis of plasma donor: Ulcerative colitis (UC) cell line: Standalone model-system marker retained for comparison grouping: cell line.; treated sample: Treated sample may need exclusion outside treatment comparisons.
Ulcerative colitis Case GSM1844298 UPN727 cells, ulcerative colitis (UC) plasma patients 15 UPN727 cells stimulated with UC15 Plasma Responder cell line: UPN727; Diagnosis of plasma donor: Ulcerative colitis (UC) cell line: Standalone model-system marker retained for comparison grouping: cell line.; treated sample: Treated sample may need exclusion outside treatment comparisons.
Healthy control Control GSM1844252 UPN727 cells, unrelated healthy control (uHC) plasma patients 01 UPN727 cells stimulated with HC01 Plasma Responder cell line: UPN727; Diagnosis of plasma donor: Healthy cell line: Standalone model-system marker retained for comparison grouping: cell line.; treated sample: Treated sample may need exclusion outside treatment comparisons.
Healthy control Control GSM1844253 UPN727 cells, unrelated healthy control (uHC) plasma patients 02 UPN727 cells stimulated with HC02 Plasma Responder cell line: UPN727; Diagnosis of plasma donor: Healthy cell line: Standalone model-system marker retained for comparison grouping: cell line.; treated sample: Treated sample may need exclusion outside treatment comparisons.
Healthy control Control GSM1844254 UPN727 cells, unrelated healthy control (uHC) plasma patients 03 UPN727 cells stimulated with HC03 Plasma Responder cell line: UPN727; Diagnosis of plasma donor: Healthy cell line: Standalone model-system marker retained for comparison grouping: cell line.; treated sample: Treated sample may need exclusion outside treatment comparisons.
Healthy control Control GSM1844255 UPN727 cells, unrelated healthy control (uHC) plasma patients 04 UPN727 cells stimulated with HC04 Plasma Responder cell line: UPN727; Diagnosis of plasma donor: Healthy cell line: Standalone model-system marker retained for comparison grouping: cell line.; treated sample: Treated sample may need exclusion outside treatment comparisons.
Healthy control Control GSM1844256 UPN727 cells, unrelated healthy control (uHC) plasma patients 05 UPN727 cells stimulated with HC05 Plasma Responder cell line: UPN727; Diagnosis of plasma donor: Healthy cell line: Standalone model-system marker retained for comparison grouping: cell line.; treated sample: Treated sample may need exclusion outside treatment comparisons.
Healthy control Control GSM1844257 UPN727 cells, unrelated healthy control (uHC) plasma patients 06 UPN727 cells stimulated with HC06 Plasma Responder cell line: UPN727; Diagnosis of plasma donor: Healthy cell line: Standalone model-system marker retained for comparison grouping: cell line.; treated sample: Treated sample may need exclusion outside treatment comparisons.
Healthy control Control GSM1844258 UPN727 cells, unrelated healthy control (uHC) plasma patients 07 UPN727 cells stimulated with HC07 Plasma Responder cell line: UPN727; Diagnosis of plasma donor: Healthy cell line: Standalone model-system marker retained for comparison grouping: cell line.; treated sample: Treated sample may need exclusion outside treatment comparisons.
Healthy control Control GSM1844259 UPN727 cells, unrelated healthy control (uHC) plasma patients 08 UPN727 cells stimulated with HC08 Plasma Responder cell line: UPN727; Diagnosis of plasma donor: Healthy cell line: Standalone model-system marker retained for comparison grouping: cell line.; treated sample: Treated sample may need exclusion outside treatment comparisons.
Healthy control Control GSM1844260 UPN727 cells, unrelated healthy control (uHC) plasma patients 09 UPN727 cells stimulated with HC09 Plasma Responder cell line: UPN727; Diagnosis of plasma donor: Healthy cell line: Standalone model-system marker retained for comparison grouping: cell line.; treated sample: Treated sample may need exclusion outside treatment comparisons.
Healthy control Control GSM1844261 UPN727 cells, unrelated healthy control (uHC) plasma patients 10 UPN727 cells stimulated with HC10 Plasma Responder cell line: UPN727; Diagnosis of plasma donor: Healthy cell line: Standalone model-system marker retained for comparison grouping: cell line.; treated sample: Treated sample may need exclusion outside treatment comparisons.

Use as Discovery Cohort

External Validation Finder

Carry Siftome's disease, organism, specimen, assay, data type, and accession into a validation project. Uncertain fields remain Unknown.